Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians-Reference-Cited by-同舟云学术

Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians

Published:2024-07-02 Issue: Volume: Page:
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Tano Marion^ORCID,Paubel Pascal^ORCID,Ribault Matthieu,Degrassat-Théas Albane^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s41669-024-00505-7.pdf

Reference28 articles.

1. Troein P et al. for IQVIA. The Impact of Biosimilar Competition in Europe 2021. White paper online 2021, Dec. [cited 2022 feb 15]. Available from https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.

2. Beck M, Michel B, Rybarczyk-Vigouret MC, Levêque D, Sordet C, Sibilia J, Velten M. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. MAbs. 2017;9(2):384–91.

3. Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970. https://doi.org/10.3389/fphar.2020.00970.

4. Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308.

5. IQVIA. Advancing biosimilar sustainability in Europe. 2018, Sept. [cited 2022 dec 7]. IQVIA institute report. Available from https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-biosimilar-sustainability-in-europe.